Differential effects of wild-type and A53T mutant isoform of alpha-synuclein on the mitochondrial proteome of differentiated SH-SY5Y cells

Journal of Proteome Research

Volumn 9, Issue 5, 2010, Pages 2390-2401

  Pennington, Kyla ^a   Peng, Jianhe ^a   Hung, Chao Chun ^a   Banks, Rosamonde E ^a   Robinson, Philip A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

2D DIGE; A53T; Alpha synuclein; ATP synthase; Complex I; Mitochondria; Mortalin; Parkinsons disease; Pyruvate dehydrogenase

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; MITOCHONDRIAL PROTEIN; PROTEIN MORTALIN; PROTEOME; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CARBOHYDRATE METABOLISM; CELL DIFFERENTIATION; CELL LINE; GEL ELECTROPHORESIS; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; MOTOR ACTIVITY; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN SYNTHESIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ALPHA-SYNUCLEIN; BLOTTING, WESTERN; CELL EXTRACTS; CELL LINE, TUMOR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MASS SPECTROMETRY; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MUTATION; NEUROBLASTOMA; OXIDATIVE PHOSPHORYLATION; PARKINSON DISEASE; PROTEIN ISOFORMS; PROTEOME; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 77952085938     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr901102d     Document Type: Article

References (71)

1. Thomas, B.; Beal, M. F. Parkinsons disease Hum. Mol. Genet. 2007, 16 (Spec No. 2) R183-94
2. Swerdlow, R. H.; Parks, J. K.; Cassarino, D. S.; Binder, D. R.; Bennett, J. P., Jr.; Di Iorio, G.; Golbe, L. I.; Parker, W. D., Jr. Biochemical analysis of cybrids expressing mitochondrial DNA from Contursi kindred Parkinsons subjects Exp. Neurol. 2001, 169 (2) 479-85
3. Bove, J.; Prou, D.; Perier, C.; Przedborski, S. Toxin-induced models of Parkinsons disease NeuroRx 2005, 2 (3) 484-94
4. Banerjee, R.; Starkov, A. A.; Beal, M. F.; Thomas, B. Mitochondrial dysfunction in the limelight of Parkinsons disease pathogenesis Biochim. Biophys. Acta 2009, 1792 (7) 651-63
5. Abou-Sleiman, P. M.; Muqit, M. M.; Wood, N. W. Expanding insights of mitochondrial dysfunction in Parkinsons disease Nat. Rev. Neurosci. 2006, 7 (3) 207-19
6. Vila, M.; Ramonet, D.; Perier, C. Mitochondrial alterations in Parkinsons disease: new clues J. Neurochem. 2008, 107 (2) 317-28
7. Weinreb, P. H.; Zhen, W.; Poon, A. W.; Conway, K. A.; Lansbury, P. T., Jr. NACP, a protein implicated in Alzheimers disease and learning, is natively unfolded Biochemistry 1996, 35 (43) 13709-15
8. Bussell, R., Jr.; Eliezer, D. Effects of Parkinsons disease-linked mutations on the structure of lipid-associated alpha-synuclein Biochemistry 2004, 43 (16) 4810-8
9. Bodner, C. R.; Dobson, C. M.; Bax, A. Multipme tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy J. Mol. Biol. 2009, 390 (4) 775-90
10. Polymeropoulos, M. H.; Lavedan, C.; Leroy, E.; Ide, S. E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; Stenroos, E. S.; Chandrasekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnson, W. G.; Lazzarini, A. M.; Duvoisin, R. C.; Di Iorio, G.; Golbe, L. I.; Nussbaum, R. L. Mutation in the alpha-synuclein gene identified in families with Parkinsons disease Science 1997, 276 (5321) 2045-7
11. Kruger, R.; Kuhn, W.; Muller, T.; Woitalla, D.; Graeber, M.; Kosel, S.; Przuntek, H.; Epplen, J. T.; Schols, L.; Riess, O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinsons disease Nat. Genet. 1998, 18 (2) 106-8
12. Zarranz, J. J.; Alegre, J.; Gomez-Esteban, J. C.; Lezcano, E.; Ros, R.; Ampuero, I.; Vidal, L.; Hoenicka, J.; Rodriguez, O.; Atares, B.; Llorens, V.; Gomez Tortosa, E.; del Ser, T.; Munoz, D. G.; de Yebenes, J. G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia Ann. Neurol. 2004, 55 (2) 164-73
13. Singleton, A. B.; Farrer, M.; Johnson, J.; Singleton, A.; Hague, S.; Kachergus, J.; Hulihan, M.; Peuralinna, T.; Dutra, A.; Nussbaum, R.; Lincoln, S.; Crawley, A.; Hanson, M.; Maraganore, D.; Adler, C.; Cookson, M. R.; Muenter, M.; Baptista, M.; Miller, D.; Blancato, J.; Hardy, J.; Gwinn-Hardy, K. alpha-Synuclein locus triplication causes Parkinsons disease Science 2003, 302 (5646) 841
14. Chartier-Harlin, M. C.; Kachergus, J.; Roumier, C.; Mouroux, V.; Douay, X.; Lincoln, S.; Levecque, C.; Larvor, L.; Andrieux, J.; Hulihan, M.; Waucquier, N.; Defebvre, L.; Amouyel, P.; Farrer, M.; Destee, A. Alpha-synuclein locus duplication as a cause of familial Parkinsons disease Lancet 2004, 364 (9440) 1167-9
15. Ross, O. A.; Braithwaite, A. T.; Skipper, L. M.; Kachergus, J.; Hulihan, M. M.; Middleton, F. A.; Nishioka, K.; Fuchs, J.; Gasser, T.; Maraganore, D. M.; Adler, C. H.; Larvor, L.; Chartier-Harlin, M. C.; Nilsson, C.; Langston, J. W.; Gwinn, K.; Hattori, N.; Farrer, M. J. Genomic investigation of alpha-synuclein multiplication and parkinsonism Ann. Neurol. 2008, 63 (6) 743-50
16. Ibanez, P.; Lesage, S.; Janin, S.; Lohmann, E.; Durif, F.; Destee, A.; Bonnet, A. M.; Brefel-Courbon, C.; Heath, S.; Zelenika, D.; Agid, Y.; Durr, A.; Brice, A. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms Arch. Neurol. 2009, 66 (1) 102-8
17. Spillantini, M. G.; Schmidt, M. L.; Lee, V. M.; Trojanowski, J. Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies Nature 1997, 388 (6645) 839-40
18. Anderson, J. P.; Walker, D. E.; Goldstein, J. M.; de Laat, R.; Banducci, K.; Caccavello, R. J.; Barbour, R.; Huang, J.; Kling, K.; Lee, M.; Diep, L.; Keim, P. S.; Shen, X.; Chataway, T.; Schlossmacher, M. G.; Seubert, P.; Schenk, D.; Sinha, S.; Gai, W. P.; Chilcote, T. J. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease J. Biol. Chem. 2006, 281 (40) 29739-52
19. Narhi, L.; Wood, S. J.; Steavenson, S.; Jiang, Y.; Wu, G. M.; Anafi, D.; Kaufman, S. A.; Martin, F.; Sitney, K.; Denis, P.; Louis, J. C.; Wypych, J.; Biere, A. L.; Citron, M. Both familial Parkinsons disease mutations accelerate alpha-synuclein aggregation J. Biol. Chem. 1999, 274 (14) 9843-6
20. Hamilton, B. A. alpha-Synuclein A53T substitution associated with Parkinson disease also marks the divergence of Old World and New World primates Genomics 2004, 83 (4) 739-42
21. Tofaris, G. K.; Garcia Reitbock, P.; Humby, T.; Lambourne, S. L.; OConnell, M.; Ghetti, B.; Gossage, H.; Emson, P. C.; Wilkinson, L. S.; Goedert, M.; Spillantini, M. G. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders J. Neurosci. 2006, 26 (15) 3942-50
22. Albani, D.; Peverelli, E.; Rametta, R.; Batelli, S.; Veschini, L.; Negro, A.; Forloni, G. Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70 FASEB J. 2004, 18 (14) 1713-5
23. Dauer, W.; Kholodilov, N.; Vila, M.; Trillat, A. C.; Goodchild, R.; Larsen, K. E.; Staal, R.; Tieu, K.; Schmitz, Y.; Yuan, C. A.; Rocha, M.; Jackson-Lewis, V.; Hersch, S.; Sulzer, D.; Przedborski, S.; Burke, R.; Hen, R. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (22) 14524-9
24. Klivenyi, P.; Siwek, D.; Gardian, G.; Yang, L.; Starkov, A.; Cleren, C.; Ferrante, R. J.; Kowall, N. W.; Abeliovich, A.; Beal, M. F. Mice lacking alpha-synuclein are resistant to mitochondrial toxins Neurobiol. Dis. 2006, 21 (3) 541-8
25. Cuervo, A. M.; Stefanis, L.; Fredenburg, R.; Lansbury, P. T.; Sulzer, D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy Science 2004, 305 (5688) 1292-5
26. Cook, C.; Petrucelli, L. A critical evaluation of the ubiquitin-proteasome system in Parkinsons disease Biochim. Biophys. Acta 2009, 1792 (7) 664-75
27. McFarland, M. A.; Ellis, C. E.; Markey, S. P.; Nussbaum, R. L. Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions Mol. Cell. Proteomics 2008, 7 (11) 2123-37
28. Li, W. W.; Yang, R.; Guo, J. C.; Ren, H. M.; Zha, X. L.; Cheng, J. S.; Cai, D. F. Localization of alpha-synuclein to mitochondria within midbrain of mice Neuroreport 2007, 18 (15) 1543-6
29. Parihar, M. S.; Parihar, A.; Fujita, M.; Hashimoto, M.; Ghafourifar, P. Mitochondrial association of alpha-synuclein causes oxidative stress Cell. Mol. Life Sci. 2008, 65 (7-8) 1272-84
30. Devi, L.; Raghavendran, V.; Prabhu, B. M.; Avadhani, N. G.; Anandatheerthavarada, H. K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain J. Biol. Chem. 2008, 283 (14) 9089-100
31. Presgraves, S. P.; Ahmed, T.; Borwege, S.; Joyce, J. N. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists Neurotox. Res. 2004, 5 (8) 579-98
32. Fernandes, N. D.; Sun, Y.; Price, B. D. Activation of the kinase activity of ATM by retinoic acid is required for CREB-dependent differentiation of neuroblastoma cells J. Biol. Chem. 2007, 282 (22) 16577-84
33. Vekrellis, K.; Xilouri, M.; Emmanouilidou, E.; Stefanis, L. Inducible over-expression of wild type alpha-synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death J. Neurochem. 2009, 109 (5) 1348-62
34. Lev, N.; Melamed, E.; Offen, D. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage Neurosci. Lett. 2006, 399 (1-2) 27-32
35. Hasegawa, T.; Matsuzaki, M.; Takeda, A.; Kikuchi, A.; Akita, H.; Perry, G.; Smith, M. A.; Itoyama, Y. Accelerated alpha-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells Brain Res. 2004, 1013 (1) 51-9
36. Hamdane, M.; Sambo, A. V.; Delobel, P.; Begard, S.; Violleau, A.; Delacourte, A.; Bertrand, P.; Benavides, J.; Buee, L. Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex J. Biol. Chem. 2003, 278 (36) 34026-34
37. Hettiarachchi, N. T.; Parker, A.; Dallas, M. L.; Pennington, K.; Hung, C. C.; Pearson, H. A.; Boyle, J. P.; Robinson, P.; Peers, C. alpha-Synuclein modulation of Ca2+ signaling in human neuroblastoma (SH-SY5Y) cells J. Neurochem. 2009, 111 (5) 1192-201
38. In Culture and biochemical analysis of cells; Spector, D. L.; Goldman, R. D.; Leinwand, L. A., Eds.; Cold Spring Harbour Lab. Press: New York, 1998; pp 41.1 - 41.7.
39. Alban, A.; David, S. O.; Bjorkesten, L.; Andersson, C.; Sloge, E.; Lewis, S.; Currie, I. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard Proteomics 2003, 3 (1) 36-44
40. Davison, E. J.; Pennington, K.; Hung, C. C.; Peng, J.; Rafiq, R.; Ostareck-Lederer, A.; Ostareck, D. H.; Ardley, H. C.; Banks, R. E.; Robinson, P. A. Proteomic analysis of increased Parkin expression and its interactants provides evidence for a role in modulation of mitochondrial function Proteomics 2009, 9 (18) 4284-97
41. Jimenez-Marin, A.; Collado-Romero, M.; Ramirez-Boo, M.; Arce, C.; Garrido, J. J. Biological pathway analysis by ArrayUnlock and Ingenuity Pathway Analysis BMC Proc. 2009, 3 (Suppl 4) S6
42. Zhang, J.; Goodlett, D. R.; Quinn, J. F.; Peskind, E.; Kaye, J. A.; Zhou, Y.; Pan, C.; Yi, E.; Eng, J.; Wang, Q.; Aebersold, R. H.; Montine, T. J. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease J. Alzheimers Dis. 2005, 7 (2) 125-33 and discussion 173-80
43. Muchowski, P. J.; Wacker, J. L. Modulation of neurodegeneration by molecular chaperones Nat. Rev. Neurosci. 2005, 6 (1) 11-22
44. Braak, H.; Ghebremedhin, E.; Rub, U.; Bratzke, H.; Del Tredici, K. Stages in the development of Parkinsons disease-related pathology Cell Tissue Res. 2004, 318 (1) 121-34
45. Licker, V.; Kovari, E.; Hochstrasser, D. F.; Burkhard, P. R. Proteomics in human Parkinsons disease research J. Proteomics 2009, 73 (1) 10-29
46. Schapira, A. H.; Cooper, J. M.; Dexter, D.; Jenner, P.; Clark, J. B.; Marsden, C. D. Mitochondrial complex I deficiency in Parkinsons disease Lancet 1989, 1 (8649) 1269
47. Bindoff, L. A.; Birch-Machin, M.; Cartlidge, N. E.; Parker, W. D., Jr.; Turnbull, D. M. Mitochondrial function in Parkinsons disease Lancet 1989, 2 (8653) 49
48. Meredith, G. E.; Sonsalla, P. K.; Chesselet, M. F. Animal models of Parkinsons disease progression Acta Neuropathol. 2008, 115 (4) 385-98
49. Keeney, P. M.; Xie, J.; Capaldi, R. A.; Bennett, J. P., Jr. Parkinsons disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled J. Neurosci. 2006, 26 (19) 5256-64
50. Goldknopf, I. L.; Sheta, E. A.; Bryson, J.; Folsom, B.; Wilson, C.; Duty, J.; Yen, A. A.; Appel, S. H. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinsons disease Biochem. Biophys. Res. Commun. 2006, 342 (4) 1034-9
51. Xun, Z.; Sowell, R. A.; Kaufman, T. C.; Clemmer, D. E. Quantitative proteomics of a presymptomatic A53T alpha-synuclein Drosophila model of Parkinson disease Mol. Cell. Proteomics 2008, 7 (7) 1191-203
52. Zhang, J.; Sokal, I.; Peskind, E. R.; Quinn, J. F.; Jankovic, J.; Kenney, C.; Chung, K. A.; Millard, S. P.; Nutt, J. G.; Montine, T. J. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases Am. J. Clin. Pathol. 2008, 129 (4) 526-9
53. Franzen, B.; Yang, Y.; Sunnemark, D.; Wickman, M.; Ottervald, J.; Oppermann, M.; Sandberg, K. Dihydropyrimidinase related protein-2 as a biomarker for temperature and time dependent post mortem changes in the mouse brain proteome Proteomics 2003, 3 (10) 1920-9
54. Shi, M.; Jin, J.; Wang, Y.; Beyer, R. P.; Kitsou, E.; Albin, R. L.; Gearing, M.; Pan, C.; Zhang, J. Mortalin: a protein associated with progression of Parkinson disease J. Neuropathol. Exp. Neurol. 2008, 67 (2) 117-24
55. Manning-Bog, A. B.; McCormack, A. L.; Purisai, M. G.; Bolin, L. M.; Di Monte, D. A. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration J. Neurosci. 2003, 23 (8) 3095-9
56. Rochet, J. C. Novel therapeutic strategies for the treatment of protein-misfolding diseases Expert Rev. Mol. Med. 2007, 9 (17) 1-34
57. Zhou, Y.; Gu, G.; Goodlett, D. R.; Zhang, T.; Pan, C.; Montine, T. J.; Montine, K. S.; Aebersold, R. H.; Zhang, J. Analysis of alpha-synuclein- associated proteins by quantitative proteomics J. Biol. Chem. 2004, 279 (37) 39155-64
58. Auluck, P. K.; Chan, H. Y.; Trojanowski, J. Q.; Lee, V. M.; Bonini, N. M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinsons disease Science 2002, 295 (5556) 865-8
59. Stelzl, U.; Worm, U.; Lalowski, M.; Haenig, C.; Brembeck, F. H.; Goehler, H.; Stroedicke, M.; Zenkner, M.; Schoenherr, A.; Koeppen, S.; Timm, J.; Mintzlaff, S.; Abraham, C.; Bock, N.; Kietzmann, S.; Goedde, A.; Toksoz, E.; Droege, A.; Krobitsch, S.; Korn, B.; Birchmeier, W.; Lehrach, H.; Wanker, E. E. A human protein-protein interaction network: a resource for annotating the proteome Cell 2005, 122 (6) 957-68
60. Narendra, D.; Tanaka, A.; Suen, D. F.; Youle, R. J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy J. Cell Biol. 2008, 183 (5) 795-803
61. Geisler, S.; Holmstrom, K. M.; Skujat, D.; Fiesel, F. C.; Rothfuss, O. C.; Kahle, P. J.; Springer, W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1 Nat. Cell Biol. 2010, 12 (2) 119-31
62. Vives-Bauza, C.; de Vries, R. L.; Tocilescu, M.; Przedborski, S. PINK1/Parkin direct mitochondria to autophagy Autophagy 2010, 6 (2) 315-6
63. Rappaport, L.; Oliviero, P.; Samuel, J. L. Cytoskeleton and mitochondrial morphology and function Mol. Cell. Biochem. 1998, 184 (1-2) 101-5
64. Chandra, S.; Gallardo, G.; Fernandez-Chacon, R.; Schluter, O. M.; Sudhof, T. C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration Cell 2005, 123 (3) 383-96
65. Moussa, C. E.; Wersinger, C.; Tomita, Y.; Sidhu, A. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine Biochemistry 2004, 43 (18) 5539-50
66. Qian, J. J.; Cheng, Y. B.; Yang, Y. P.; Mao, C. J.; Qin, Z. H.; Li, K.; Liu, C. F. Differential effects of overexpression of wild-type and mutant human alpha-synuclein on MPP+-induced neurotoxicity in PC12 cells Neurosci. Lett. 2008, 435 (2) 142-6
67. Li, W.; Lee, M. K. Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity J. Neurochem. 2005, 93 (6) 1542-50
68. Wersinger, C.; Prou, D.; Vernier, P.; Niznik, H. B.; Sidhu, A. Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity Mol. Cell. Neurosci. 2003, 24 (1) 91-105
69. Bertoncini, C. W.; Fernandez, C. O.; Griesinger, C.; Jovin, T. M.; Zweckstetter, M. Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation J. Biol. Chem. 2005, 280 (35) 30649-52
70. Li, J.; Uversky, V. N.; Fink, A. L. Effect of familial Parkinsons disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein Biochemistry 2001, 40 (38) 11604-13
71. Goris, A.; Williams-Gray, C. H.; Clark, G. R.; Foltynie, T.; Lewis, S. J.; Brown, J.; Ban, M.; Spillantini, M. G.; Compston, A.; Burn, D. J.; Chinnery, P. F.; Barker, R. A.; Sawcer, S. J. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinsons disease Ann. Neurol. 2007, 62 (2) 145-53